Third positive pivotal Phase III clinical trial of AstraZeneca’s IL-33-targeting biologic further demonstrates its benefits in COPD
IMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver...
First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials
Joshua Jackson is joined by Gritty to take the body check off the ice.
Based on DESTINY-Breast05 Phase III trial results which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1 ...
CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with 77% of patients progression free at three...
Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol...
US ACT on Health Equity contributions support AstraZeneca’s long-term ambition in health equity and total more than $18 million to date
Strong commercial performance and excellent pipeline delivery in a continuing catalyst-rich period
Based on results from TROPION-Breast02, showing AstraZeneca and Daiichi Sankyo’s DATROWAY significantly improved overall survival vs. chemotherapy in this patient population ...